Briefing
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study.
In the NeoRHEA trial of neoadjuvant palbociclib plus endocrine therapy, the RaDaR assay was used to measure ctDNA before treatment, during treatment, and after surgery.
- Design: Evidence level 3
- Assay: RaDaR
NPJ Breast CancerPubMed 41350280DOI 10.1038/s41523-025-00852-6